News about "Boehringer Ingelheim"

Sanofi and Novartis Reach Separate Agreements with US Government to Lower Drug Prices and Support Innovation

Sanofi and Novartis have separately entered into agreements with the US government to reduce medicine prices for American patients while reinforcing long-term commitments to US-based manufacturing, research and innovation, marking a coordinated push to balance affordability with sustained pharmaceutical investment.

Boehringer Ingelheim | 22/12/2025 | By News Bureau

Takeda Becomes a BaseLaunch Partner

BaseLaunch has added Takeda as a new pharmaceutical partner to its biotech venture incubator, expanding its network of global pharma backers supporting and funding early-stage drug development startups.

Boehringer Ingelheim | 19/12/2025 | By News Bureau

Lung Cancer Canada and Boehringer Ingelheim Canada Partner to Advance NSCLC Diagnostics

Lung Cancer Canada and Boehringer Ingelheim have launched a two-stage initiative to accelerate innovation in NSCLC diagnostics. The effort begins with a national Diagnostic Innovation Lab to identify key barriers in diagnosis, followed by an innovation challenge seeking solutions to close those gaps.

Boehringer Ingelheim | 29/11/2025 | By Dineshwori

Boehringer Ingelheim Acquires Licence from Kyowa Kirin to Develop Treatment for Autoimmune Diseases

Boehringer Ingelheim has acquired a licence from Kyowa Kirin to develop a small molecule programme targeting autoimmune diseases. The collaboration aims to address significant unmet medical needs and strengthen Boehringer’s pipeline of innovative therapies for patients with inflammatory and immune-related conditions.

Boehringer Ingelheim | 31/10/2025 | By Dineshwori |  135

Boehringer Ingelheim's Zongertinib Shows 77 Percent Response Rate in HER2-Mutant NSCLC

Boehringer Ingelheim presented Phase Ib Beamion LUNG-1 trial data at ESMO 2025, showing that zongertinib achieved a 77 percent Objective Response Rate (ORR) in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC.

Boehringer Ingelheim | 24/10/2025 | By Dineshwori |  166

Boehringer Ingelheim's Jascayd Receives US FDA Approval for Oral Treatment Option for Adults with IPF

Jascayd is the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. This represents a novel mechanism of action that exerts both antifibrotic and immunomodulatory effects, thereby slowing the decline in lung function in IPF patients.

Boehringer Ingelheim | 10/10/2025 | By Dineshwori |  279

Palatin Receives USD 6.5M Milestone Payment Under Retinal Disease Collaboration with Boehringer Ingelheim

Palatin Technologies, the US-based biopharmaceutical company focused on developing medicines that modulate the melanocortin receptor system, announced it has achieved a research milestone under its collaboration with Boehringer Ingelheim, triggering a 6.5 million payment to the company.

Boehringer Ingelheim | 23/09/2025 | By Dineshwori

Boehringer Ingelheim Unveils VETMEDIN Solution

VETMEDIN Solution, now available in the US, provides the same dual mode of action as VETMEDIN® Chewable Tablets.

Boehringer Ingelheim | 25/11/2024 | By Aishwarya |  285

PhoreMost Join Hands with Boehringer Ingelheim

PhoreMost Ltd. has made a multi-project target discovery collaboration with Boehringer Ingelheim.

Boehringer Ingelheim | 04/06/2024 | By Aishwarya |  412

Boehringer Ingelheim Teams Up with Quallent to Expand Access to adalimumab-adbm Injection

Boehringer Ingelheim has signed a deal with Quallent Pharmaceuticals to help expand patient access to citrate-free adalimumab-adbm, Boehringer's biosimilar to Humira (adalimumab), in the US.

Boehringer Ingelheim | 14/05/2024 | By Aishwarya |  655